Last updated: 2026-09-05 11:58:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Exicure, Inc. (XCUR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.27, with a market capitalization of $8.44M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.05 to $9.48. This page covers its latest market performance, valuation, price trends and company information.
$8.44M | |
$1.23 | |
$576.00 | |
$1.05 | |
$1.23 | |
16.36K | |
-- | |
-- | |
$9.48 | |
$1.05 | |
-- | |
-- |
Exicure, Inc. (XCUR) last closed at $1.23 as of 2026-09-04 21:39:00, unchanged from the previous close of $1.23.
During the latest regular trading session, XCUR traded between $1.05 and $576.00, with a volume of 16.36K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Exicure, Inc. (XCUR) moved from $1.31 to $1.27, representing a decline of 2.98% ($0.04).
The stock traded between $1.23 and $1.35 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 30.48 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 2.6%
XCUR is currently trading at $1.27, placing it 2.6% of the way from its 52-week low of $1.05 to its 52-week high of $9.48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Exicure, Inc. (XCUR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.